HC Wainwright Predicts Reduced Earnings for SOPHiA GENETICS

SOPHiA GENETICS SA (NASDAQ:SOPH) – Stock analysts at HC Wainwright decreased their FY2029 earnings per share (EPS) estimates for shares of SOPHiA GENETICS in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.31 for the year, down from their prior forecast of $0.34. HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for SOPHiA GENETICS’s current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for SOPHiA GENETICS’s FY2030 earnings at $0.72 EPS.

A number of other brokerages have also recently issued reports on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research boosted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Trading Down 7.9%

SOPHiA GENETICS stock opened at $6.30 on Thursday. SOPHiA GENETICS has a 1 year low of $2.96 and a 1 year high of $7.21. The firm’s 50-day moving average is $5.54 and its 200-day moving average is $5.12. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The company has a market cap of $528.51 million, a P/E ratio of -5.48 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 153.15%.

Insiders Place Their Bets

In other SOPHiA GENETICS news, insider Zhenyu Xu sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $6.92, for a total transaction of $69,200.00. Following the completion of the transaction, the insider owned 600,887 shares in the company, valued at approximately $4,158,138.04. The trade was a 1.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $5.66, for a total value of $28,300.00. Following the transaction, the insider directly owned 223,387 shares in the company, valued at $1,264,370.42. This trade represents a 2.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 256,092 shares of company stock worth $1,492,420 over the last 90 days. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SOPH. 1492 Capital Management LLC acquired a new position in shares of SOPHiA GENETICS during the 4th quarter valued at $973,000. Royce & Associates LP acquired a new position in SOPHiA GENETICS during the fourth quarter worth about $2,009,000. Hodges Capital Management Inc. acquired a new position in SOPHiA GENETICS during the first quarter worth about $2,157,000. Royal Bank of Canada raised its position in SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the 1st quarter valued at about $1,772,000. 31.59% of the stock is currently owned by institutional investors.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its fiscal 2026 revenue outlook to $94 million–$96 million, above the roughly $93.4 million analyst consensus. Management continues to target adjusted EBITDA breakeven by year-end, which could improve confidence in the company’s path toward profitability. 2026 revenue outlook article
• Positive Sentiment: The company entered a multi-year collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The agreement may expand SOPH’s customer base and create longer-term opportunities in oncology testing. AstraZeneca partnership article
• Positive Sentiment: HC Wainwright raised its price target from $12 to $14 and BTIG Research increased its target from $8 to $9; both firms maintained Buy ratings. These revisions suggest some analysts see substantial upside if SOPH delivers on its growth and profitability targets. Analyst price target updates
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu collectively sold 35,000 shares worth approximately $242,350. Because all three transactions were conducted under pre-arranged Rule 10b5-1 plans and represented relatively small reductions in ownership, the sales provide limited information about management’s current outlook.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the $0.21 loss analysts expected. Although revenue of $23.31 million exceeded the $21.72 million consensus, the company remains deeply unprofitable, with a negative net margin and analysts projecting a full-year loss. The earnings miss likely contributed to selling pressure. Q2 2026 earnings call transcript

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.